Amundi MSCI Europe Growth (EPA:CG9)
France · Delayed Price · Currency is EUR | Assets | 178.15M |
| Expense Ratio | 0.35% |
| PE Ratio | 23.43 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +24.69% |
| Volume | 283 |
| Open | 346.90 |
| Previous Close | 344.20 |
| Day's Range | 346.90 - 349.10 |
| 52-Week Low | 286.55 |
| 52-Week High | 362.00 |
| Beta | 0.79 |
| Holdings | 226 |
| Inception Date | Feb 26, 2009 |
About CG9
Amundi MSCI Europe Growth is an exchange traded fund launched and managed by Amundi Luxembourg S.A. It is co-managed by Amundi Asset Management. The fund invests in the public equity markets of developed markets in Europe. It uses derivatives such as swaps to invest in the stocks of companies operating across diversified sectors. The fund invests in the growth stocks of large-cap and mid-cap companies. It seeks to replicate the performance of the MSCI Europe Growth Strategy Index, by employing synthetic replication methodology. The fund was formerly known as Amundi ETF MSCI Europe Growth UCITS ETF. Amundi MSCI Europe Growth was formed on February 3, 2009 and is domiciled in Luxembourg.
Performance
CG9 had a total return of 24.69% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.26%.
Top 10 Holdings
33.01% of assets| Name | Symbol | Weight |
|---|---|---|
| ASML Holding N.V. | ASML | 8.20% |
| AstraZeneca PLC | AZN | 4.73% |
| Novartis AG | NOVN | 4.35% |
| SAP SE | SAP | 2.72% |
| Schneider Electric S.E. | SU | 2.44% |
| Siemens Energy AG | ENR | 2.23% |
| LVMH Moët Hennessy - Louis Vuitton, Société Européenne | MC | 2.16% |
| Rolls-Royce Holdings plc | RR | 2.15% |
| ABB Ltd | ABBN | 2.08% |
| UBS Group AG | UBSG | 1.94% |